CS
ADVM

Candriam SCA’s Adverum Biotechnologies ADVM Stock Holding History

Candriam SCA’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-29,849
Closed -$3.11M – 886
2021
Q1 		$3.11M Hold
29,849
– – 0.03% 450
2020
Q4 		$3.24M Sell
29,849
-509
-2% -$63K 0.03% 461
2020
Q3 		$3.13M Buy
30,358
+7,500
+33% +$1.12M 0.03% 428
2020
Q2 		$4.77M Buy
22,858
+2,858
+14% +$506K 0.05% 344
2020
Q1 		$2.25M Hold
20,000
– – 0.03% 506
2019
Q4 		$2.3M Buy
+20,000
New +$1.76M 0.02% 520

Other funds holding ADVM

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Candriam SCA's ADVM Position: Q2 2021 in Review

Candriam SCA sold out of Adverum Biotechnologies (ADVM) in Q2 2021, closing a stake of 29,849 shares — an estimated $3.11M sold.

Candriam SCA first reported a position in ADVM in Q4 2019 and held it in 6 quarters. The position peaked at $4.77M in Q2 2020. 118 funds tracked by Wall St. Rank hold ADVM as of Q2 2021.

  • Candriam SCA reported no remaining Adverum Biotechnologies position as of Q2 2021 after selling out during the quarter.
  • Candriam SCA sold 29,849 Adverum Biotechnologies shares in Q2 2021, an estimated $3.11M.
  • Candriam SCA first reported a position in Adverum Biotechnologies in Q4 2019 and held it in 6 quarters.
  • Candriam SCA's Adverum Biotechnologies position peaked at $4.77M in Q2 2020.
  • 118 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2021.

Based on Candriam SCA's 13F filing for Q2 2021, filed 20 Jul 2021.